Xigris 欧盟 - 英文 - EMA (European Medicines Agency)

xigris

eli lilly nederland b.v. - drotrecogin alfa (activated) - sepsis; multiple organ failure - antithrombotic agents - xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. the use of xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).

XIGRIS (5MG/VIAL) POWDER FOR SOLUTION 加拿大 - 英文 - Health Canada

xigris (5mg/vial) powder for solution

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 5mg - drotrecogin alfa (activated) 5mg - other miscellaneous therapeutic agents

XIGRIS  (20MG/VIAL) POWDER FOR SOLUTION 加拿大 - 英文 - Health Canada

xigris (20mg/vial) powder for solution

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 20mg - drotrecogin alfa (activated) 20mg - other miscellaneous therapeutic agents

Xigris 5mg powder for solution for infusion vials 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

xigris 5mg powder for solution for infusion vials

eli lilly and company ltd - drotrecogin alfa - powder for solution for infusion - 5mg

Xigris 20mg powder for solution for infusion vials 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

xigris 20mg powder for solution for infusion vials

eli lilly and company ltd - drotrecogin alfa - powder for solution for infusion - 20mg